Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

Speculation about the alleged findings of a study on long COVID and post-vaccination syndrome spread widely among vaccine ...

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease ...

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein ... protection against SARS-CoV-2 variants.

This work reveals how the SARS-CoV-2 spike protein’s membrane-binding domain facilitates viral entry by bridging the viral and host cell membranes. It highlights the role of a specific peptide ...

Quantum mechanical modeling allowed the team to develop an initial set of predictions about the role of mutations on infectivity and immune response evasion of Omicron and other SARS-CoV-2 variants ...

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Researchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, ...

CoV-2, the virus that causes Covid-19 disease, first emerged in China’s Wuhan, the evidence so far makes a convincing case ...